This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ABTL0812

Ability Pharmaceuticals, SL

Drug Names(s): ABTL-0812, sodium 2-hydroxylinoleate

Description: ABTL0812 interferes with key processes related with cell proliferation and survival. It affects two key cellular processes: i) the inhibition of akt and the mTORC1 and mTORC2 pathways which are involved in protein synthesis and cell survival, and ii) DNA synthesis through the inhibition of the gene expression of dihydrofolate reductase (DHFR), needed for cell proliferation. By blocking these two key cellular functions, tumor cells finally die by Autophagy.

In animal models of immunosuppressed mice with lung and pancreatic cancer xenografts, after a 4 weeks treatment the molecule reduced tumor growth by 70% and complete tumor growth arrest was observed in 10% of treated mice.

Deal Structure: Lipopharma is the inventor of the patent covering the drug candidates being developed by Ability Pharmaceuticals.

Ability and SciClone
In May 2016, Ability Pharmaceuticals announced that the company has entered into an agreement with SciClone Pharmaceuticals, granting SciClone an exclusive license to develop and market ABTL0812 in China and some adjacent territories.

Under the terms of the agreement, Ability Pharma has granted SciClone exclusive rights to develop, promote, market, distribute and sell ABTL0812 in China, as well as Hong Kong, Macau, Taiwan and Vietnam, getting access to follow-up compounds. Ability Pharma will receive an upfront payment and research funding as well as development, regulatory and sales milestone payments, potentially totaling more than $20 million; Ability Pharma will also be eligible to receive royalties on sales. SciClone will be responsible for all aspects of development, product registration and commercialization in the...See full deal structure in Biomedtracker

Partners: Lipopharma Therapeutics SL SciClone Pharmaceuticals, Inc.


ABTL0812 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug